Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: J Immunol. 2013 Mar 27;190(9):4848–4860. doi: 10.4049/jimmunol.1200870

Figure 8. Tolerogenic donor DCs induce skin transplant survival when recipient mice that lack CD8+ DCs are treated with anti-CD40L antibody therapy.

Figure 8

Baft3−/− (A) and B6 (B) mice received 2×106 B6Kd DCs treated with DexD3. Control mice received PBS. Seven days later mice received a B6Kd skin transplant. In addition, some mice were treated with 500μgs of MR1 4 and 7 days prior to, and on the day of transplantation (filled symbols). Mice were monitored daily and rejection was deemed to have occurred when no viable skin remained. The mean survival time (MST) + SEM is shown (*p<0.05 **p<0.01** p<0.001) and the number of animals per condition (n). Data shown represents 3 and 2 independent experiments, respectively.